Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY)
Horga et al., Future Virology, doi:10.2217/fvl-2023-0115
https://c19early.org/horga.html